Although the AS patient eligibility criteria and monitoring protocols vary widely(5-8), as detailed in Table 1, they often include total serum prostate specific antigen (PSA), clinical T stage, Gleason score, total number of positive biopsy cores, percentage of the length of biopsy cores affected by cancer, the time intervals for patient monitoring, and life expectancy. Here, KLK3 is linked to cancer.